MARKET
IPO

VOGX

Vogenx
VOGX
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-08-06
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-48.15~-40.74
-
-
152.96M~180.77M
-
2026-07-15
Public Filing
View Prospectus
Pending
Offering
Price Range: 11.00~13.00
Shares to be Issued: 6250.00K
2026-08-05
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 13.91M
2026-08-06
Listed
U.S. IPO Weekly Recap: Jersey Mike's And Reformation Underwhelm
Seeking Alpha · 4h ago
About VOGX
Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The Company's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.

Webull offers Vogenx stock information, including NASDAQ: VOGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOGX stock methods without spending real money on the virtual paper trading platform.